 |
|
|
 |
|
New Combo Treatment Extends Kidney Cancer Survival
|
 |  |  |  | Related Healthscout Videos |  |
|
Page: << Prev | 1 | 2 "This can result in better survival and better quality of life for survivors. On the other hand, with more and more drugs and combinations, it may become harder to see the impact of an individual drug," he added.
Another expert lauded the paper.
"This article provides another outstanding example of how a greater understanding of the biology of kidney cancer can lead to successful treatments that delay tumor growth," said Dr. James Brugarolas, an assistant professor in the division of oncology at the Simmons Comprehensive Cancer Center at the University of Texas Southwestern Medical Center at Dallas.
Text Continues Below

"An important question that remains to be addressed is whether bevacizumab alone would offer similar benefit with respect to slowing down tumor progression as the bevacizumab/interferon combination, with perhaps less toxicity," Brugarolas said.
More information
For more on kidney cancer, visit the U.S. National Cancer Institute.
Page: << Prev | 1 | 2
|
Copyright © 2007 ScoutNews, LLC. All rights reserved.
Last updated 12/21/2007
|
 |

SOURCES: Mayer Fishman, M.D., Ph.D., assistant professor, department of interdisciplinary oncology, Moffitt Cancer Center, University of South Florida, Tampa; James Brugarolas, M.D., Ph.D., assistant professor, division of oncology, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center at Dallas; Dec. 22/29, 2007, The Lancet
|